Levosimendan in patients with pulmonary hypertension due to heart failure with preserved ejection fraction: results of the LEVEL trial

29 August 2026 (11:15 - 11:30)

Organised by:

Video

Sign in for access options

About the speaker

Professor Sanjiv Shah

Northwestern University, Chicago (United States of America)

4 More presentations in this session

Presentation thumbnail

Treatment with Ralinepag Improves Outcomes in Patients with Connective Tissue Disease Associated with Pulmonary Arterial Hypertension: Results from the Phase 3 ADVANCE Outcomes Study

Professor G. Giannakoulas (Thessaloniki, GR)

Presentation thumbnail

Automated Detection of Pulmonary Hypertension from a Single Apical Four-Chamber Echocardiographic Clip: development on the largest RHC-confirmed cohort to date and multinational external validation

Doctor F. Alenezi (Durham, US)

Presentation thumbnail

Pulmonary Arterial Hypertension in Families with Hereditary Hemorrhagic Telangiectasia: A Nationwide Family Registry

Doctor Y. Zhou (Guangzhou, CN)

Presentation thumbnail

ARTISAN: Afterload Reduction To Improve Right Ventricular Structure And FuNction

Professor I. Lang (Vienna, AT)

Access the full session

Session thumbnail

Late-Breaking Clinical Science: pulmonary hypertension

The Event

Event poster

ESC Congress 2026

29 August 2026 11:15 CET

You may be interested in

Congress Session

Hottest trials (1)

9 May 2026

Congress Session

Shaping the future management of pulmonary hypertension

1 September 2024

Congress Presentation

The experience of more than three hundred levosimendan administrations: what we have learned

29 August 2025

Congress Session

Practice-changing studies from NEJM 2024

30 August 2024

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources